We at Magellan Biologics & Consulting are proud of this great achievement for our sister Company ExcellGene SA and congratulate, together with the whole ExcellGene team, all the consortium members: Bharat Biotech International Limited and the University of Sydney on their commitment to the progress of science and medicine! This new milestone for CEPI (Coalition for Epidemic Preparedness Innovations) is of paramount importance in our global effort towards the objective of a long-term control of the #sarscov2 virus.
A novel drug produced in CHO cells has recently been approved by the FDA
Tislelizumab-jsgr is a PD-1 blocking antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic
29 March 2024
